Active ingredientSaquinavirCat. No. P-S013-001CAS 127779-20-8Family · Pharmaceutical analytical standards
Saquinavir
An HIV protease inhibitor, patented in 1988 and first marketed in 1995: it was the first protease inhibitor approved by the US FDA and is used with other medicines against HIV and AIDS. This family brings together the active ingredient, pharmacopoeial impurities and labelled standards.
Did you know?On its own it is poorly and variably absorbed: it is given together with ritonavir, which blocks the CYP3A4 enzyme and raises its levels in the blood.
Go to the active ingredient →Active ingredientSaquinavirCat. No. P-S013-001CAS 127779-20-8
Active ingredientSaquinavir MesylateCat. No. P-S013-002CAS 149845-06-7
Pharmacopoeial impuritySaquinavir Mesylate EP Impurity ACat. No. P-S013-003
Pharmacopoeial impuritySaquinavir Mesylate EP Impurity BCat. No. P-S013-004
Pharmacopoeial impuritySaquinavir Mesylate EP Impurity CCat. No. P-S013-005CAS 136522-17-3
Pharmacopoeial impuritySaquinavir Mesylate EP Impurity DCat. No. P-S013-006
Pharmacopoeial impuritySaquinavir Mesylate EP Impurity ECat. No. P-S013-007
Pharmacopoeial impuritySaquinavir Mesylate EP Impurity FCat. No. P-S013-008
Pharmacopoeial impuritySaquinavir Mesylate EP Impurity GCat. No. P-S013-009
Pharmacopoeial impuritySaquinavir Mesylate EP Impurity HCat. No. P-S013-010
Isotopically labelledSaquinavir-d6Cat. No. P-S013-011No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Reference substanceSaquinavir mesilate CRSEDQM code Y0001049Family SaquinavirNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.